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ABSTRACT
Human umbilical vein endothelial (HUVE) cells have been
previously reported to express the genes for the A and B chain
peptides

of

the

dimeric

molecule

Platelet-Derived

Growth

Factor (PDGF) and to secrete PDGF-related factors into culture
media.

Anti-human PDGF IgG affinity chromatography was used

to purify PDGF-related activity from HUVE cell conditioned
media.

Immunoblot analysis of the affinity purified proteins

with anti-PDGF IgG and antibodies specific for the A or B
chain peptides of PDGF combined with chemotactic and mitogenic
assays revealed that the major PDGF immunorelated molecule
secreted by HUVE cells is a monomer of approximately 36-38 kd
MW and that less than 15% of the purified biologically active
molecules are PDGF A or B chain peptides.

Screening of an

HUVE cell eDNA library in the expression vector lambda gtl1

with the

anti-PDGF

antibody

resulted

in

the

cloning and

sequencing of a cDNA with an open reading frame encoding a 38
kd cysteine-rich secreted protein which our data indicate is
the major PDGF-related mitogen secreted by human vascular
endothelial cells.

The protein has a 45% overall homology to

the translation product of the v-src-induced CEF-10 mRNA from
chick

embryo

fibroblasts.

We

have

Connective Tissue Growth Factor (CTGF).

termed

this

mitogen
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INTRODUCTION

The peptide growth factors are a diverse group of protein
hormones which are involved in the migration, proliferation
and differentiation of various cell types.

Growth factors act

in a paracrine or autocrine fashion by binding to specific
cell surface receptors on their target cells and mediate their
biological effects either directly by receptor phosphorylation
of

cytoplasmic

proteins

or

through

cytoplasmic second messengers.
includes

kinase

activation

the

activation

of

The result of these mechanisms
and

protein

phosphorylation,

increase in calcium and other cation concentration, induction
of transcription of specific genes and translation of proteins
necessary for progression through the cell cycle. (Pardee, 1989
for

review.)

Both

growth

al.,1983;Doolitle et al.,1983)
(Downward et

factors

et

and growth factor receptors

al.,1984;Sherr et

cellular oncogenes,

(Waterfield

al.,1985)

are

related

to

thereby linking the control of normal

growth with pathological growth and neoplasia.

Clinically,

a thorough understanding of the peptide growth factors will
lead to therapies which will augment normal processes such as
wound healing and inhibit the pathological effects of these
factors in tumorogenesis and cancer metastasis.
The growth factors involved in epithelial and mesenchymal
ca~~

development and regeneration work in concert to cause the

migration and proliferation of cells in areas needed such as
epithelia of the skin and gut or in the healing of a wound.

2

Studies done in fibroblasts (stiles et al.,1979) demonstrated
that stimulation with at least two types of growth factors are
necessary for cells to enter and progress through the cell

cycle.

Platelet-Derived

Growth

Factor

(PDGF)

has

been

described as a competence factor and binding of PDGF to cell

surface receptors of quiescent fibroblasts causes cells to
move from the
(Stiles

et

Go

stage to the

al.,1979).

The

G1

stage of the cell

phase

G1

is

a

cycle

preparatory,

biosynthetic stage characterized by protein phosphorylation,
calcium ion increases, kinase activation and the induction of
the

fos

(Greenburg

and

Ziff,1984)

al., 1983 iCochran et al,1983)

genes,

proteins involved in gene regulation.

and

myc

(Kelly

et

which produce nuclear
Cells made competent

by the action of PDGF will remain in the G1 stage and not
progress further in the cell cycle unless stimulated by a

progression factor such as Epidermal Growth Factor (EGF) or
Insulin-like Growth Factor (IGF).

These progression factors

will cause the fibroblasts to enter the S phase of the cycle
in

which

aI.,19S3).

DNA

is

duplicated

(Leof,et

al.,1982;Leof

et

Cells which enter -the S phase will complete the

cell cycle by progressing through

G~

and into the mitotic M

stage without further external stimulation by growth factors
or other agents.

stimulation with a progression factor first

and then a competence factor results in cells only entering

the

G1

phase of

progression factor

the

cycle.

Further stimulation with

is needed to enter the-- S phase.

a

This

3

indicates that certain induced proteins and second messengers
in the competence stage are necessary for proper responses to
progression factors and completion of the cell cycle (Stiles

et ale ,1979).

The work with fibroblasts demonstrates that the

regulation of cellular proliferation is a complex process that
requires multiple intracellular signals and external stimuli
to

induce

entry

Therefore,

and

completion

of

the

mitotic

cycle.

the availability of competence and progression

factors to target cells in vivo must be optimized in both time
and place for tissue regeneration and development to occur.
Investigations

determined

into

that

functionally

the

there

similar

nature

are

of

growth

families

molecules

of

factors

have

structurally

which

are

and

expressed

differentially by cells and tissues and this multiplicity
ensures that the necessary biological activity is present when

needed.

A

involved

brief

in

synopsis

connective

of

tissue

these

families

growth

is

of

factors

instrumental

in

understanding the work we have done with PDGF and growth
factors biologically related to PDGF.
Epidermal Growth Factor

(EGF)

was originally purified

from mouse salivary glands (Cohen, 1962) and later from human
urine

(Cohen

Orth,1983).
acid

peptide

and

Carpenter, 1975)

and

platelets

(Oka

and

The biologically active molecule is a 53 amino
containing

(Gregory,1975iTaylor

three

internal

et al. ,1972).

EGF

disulfide
is

a

epithelial and endothelial cells and fibroblasts.

bonds

mitogen

for

The ligand
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binds a 170 kd cell surface receptor which is related to the
erb

B

oncogene (Downward et al.,1984).

A related molecule,

Transforming Growth Factor alpha (TGF-a) exists in multiple
species ranging from 5-20 kd with the smallest form being a
50 amino acid molecule with 30% homology to EGF including

conservation
al.,1984).

of

the

six cysteine

residues

(Marquardt

et

This sequence homology and formation of the three

intramolecular disulfide bonds may indicate similar protein

tertiary structure and explain binding of both EGF and TGF-Q
to

the

same

cell

surface

(Massague, 1983) •

receptor

In

addition to the EGF and TGF-a peptides, a larger molecule of
27-30 kd has been identified in human platelets which is
immunologically related to these two molecules and binds the
same receptors (Oka and Orth,1983iBowen-pope and Ross,1983).
Transforming Growth Factor beta
dimeric molecule composed of two

(TGF-P)

identical

is

a

kd

monomers held

together by nine disulfide bonds (Derynck et al.,1985).
~

25

TGF-

has been identified in various tissues and purified from

human platelets

(Assoian et al .., 1983)

(Frolich,et al.,19B3).

and human placenta

TGF-p has been shown to be a mitogen

for a variety of mesenchymal cell types in monolayer culture
(Shipley et al., 1985; Roberts et al., 1985; Massague, 1984) ,
although further investigation has indicated that this may be
an indirect effect involving the induction of PDGF related

molecules (Leaf et al.,19B6;Soma and Grotendorst,1989).
f3

is an inhibitor of endothelial

TGF-

(Baird> and Durkin, 1986 ;

5

Frater-Schroder et al.,1986;

Heimark et al.,1986;Muller et

al.,19B7; Takahara et al.,19S7)
et

al.,1986iTucker

et

and epithelial cells (Masui

al.,1984)

and

regulates

the

differentiation of bronchial epithelial and other cell types
(Masui et al 1986).

Two different TGF-p monomers (Beta 1 and

Beta 2) have been identified and share greater than 70% amino
acid sequence homology, including conservation of all cysteine

A third monomer (TGF-Beta

residues (Cheifetz et al.,19B7).

3) has recently been cloned (ten Dijke et al.,1988).

Fibroblast Growth Factor (FGF) was originally identified
from extracts of pituitary and brain as an activity which
stimulated

the

of

growth

Gospodarowicz,1974).

3T3

cells

(Armelin,1973;

The biological activity was later shown

to be due to two proteins,

acidic FGF

(pI

5. 6)

(Maciag, et

al.,19B4;Thomas,et al.,1984) and basic FGF (pI >9.0)
ale , 1985)

which

share a

(Esch,et al.,1985).

55%

amino

acid

(Esch,et

sequence homology

A human cDNA clone for acidic FGF (Jaye

et al.,1986) has been sequenced as has a eDNA clone for basic
FGF (Abraham et al.,1986) and both messages indicate 155 amino
acid precursor molecules.
peptides
molecules

and
but

rupture.

therefore
are

The FGF proteins do not have leader
are

released

not

thought

upon

tissue

to

be

damage

and

cell

These growth factors are mitogenic for cells of

mesenchymal

origin

including

fibroblasts,

endothelial

smooth muscle cells, myoblasts and osteoblasts.
growth

secreted

factor

molecules

have

been

found

in

and

Fibroblast

most

tissues
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examined and range in size from 15,000 to 18,000 MW.

Higher

forms have been identified and multiple forms

of mRNA

MW

transcripts

detected,

processing and
been

mRNA

identified

suggesting

splicing.

which

differential

protein

Several other proteins have

constitute

family

a

of

homologous

proteins with similar biological activities.

The

FGF-5

protein is a 267 amino acid molecule with 43% homology to FGF
which is mitogenic for both fibroblasts and endothelial cells
(Zhan et al.,1988).

The gene product of the hst\K-fgf gene

is a 206 amino acid protein with similar biological activity
which also has 43% amino acid homology to FGF and was isolated
from a Karposi's sarcoma (Delli-Bovi et al.,19S7; Del1i-Bavi
et al., 1988) .

Both the FGF-5 and hst\K-fgf proteins are

translated with a signal sequence and are secreted into media
from transfected tissue culture cells. A fifth member of this
family is the product of the int-2 gene which has a 44% amino
acid sequence homology to FGF (Dickson and Peters,1987).
Platelet-Derived
characterized as
effect

on

a

Growth

Factor

(PDGF)

mitoattractant due

fibroblasts

and

smooth

to

muscle

its

has

been

chemotactic

cells

at

lower

concentrations (0.1-1.0 nM) and its mitogenic effect on these
cells at higher concentrations

(0.5-5 nM)

(Grotendorst and

Martin,1986).

PDGF has not been shown to be mitogenic on

epithelial

or

endothelial

identified

(Ross

et

cells.

al.,1974;Kohler

PDGF
and

was

originally

Lipton, 1974)

and

purified (Antoniades et al.,1979;Heldin et al.,1979;Heldin et

7

al. , 1981)

from

the

alpha

granules

of

human

platelets.

Platelet PDGF is a dimeric molecule which migrates on SDSpolyacrylamide gels at approximately 30 kd.
dimeric PDGF yields A chain
peptides

which

share

a

(17 kd)

60%

Reduction of

and B chain

sequence

homology

conservation of seven cysteine residues.

(14 kd)
including

The gene for the A

chain is located on chromosome 7 (Bonthron,et al.,1988) and
the B chain (c-sis) gene on chromosome 22 (Dalla Favera et,al.
1981).

The monomeric peptides are not biologically active as

a mitogen (Antoniades,1981) or a chemoattractant (Grotendorst
et al., 1981).

The three possible isoforms of PDGF, the AA and

BB homodimers and the AS heterodimer, are found naturally and
all are biologically active (Heldin et al.,1986; Betsholtz et
al.,1985; Stroobant and Waterfield,1984).

Two high affinity

cell surface receptors have been identified and are tyrosine
kinases

(Heldin

et

al.,1981iGronwald

al.,198S;Heldin et al.,1988).

et

al.,1988;Hart

et

Differential binding of the

PDGF isoforms to these receptors has been reported with the
type alpha receptor binding all three isoforms and type beta
binding only the BB and AB dimers (Bowen-Pope et al.,1989).
The B chain of PDGF demonstrates sequence homology with the
v-sis oncogene and may be involved in cell transformation by
an

autocrine

mechanism

(Doolittle

al.,1983;Owen et al,1984).
bacterial

is

ale ,1983 ; Robbins

et

Human macrophages activated with

endotoxin secrete a

culture media which

et

PDGF

related

neutralized by

activity

~anti-PDGF

into

antibody

8

(Martinet et ale ,1986).
with

an

activity

anti-PDGF
is

Immunoblots of this conditioned media

antibody

produced

by

indicate
a

16

that

kd

the

biological

monomeric

molecule

antigenically related to PDGF and has been termed Macrophage
Derived Growth Factor (MDGF)

(Pencev and Grotendorst,1988).

Partial amino acid sequence was obtained for this peptide
indicates that it is not related to the A or B chain of
platelet PDGF but

is

a

product of the connective Tissue

Activating Peptide III gene, which has recently been cloned
and sequenced (Wenger,et a1.,1989).

The biological activity

may be due to similar conformation of PDGF dimers and the
monomeric MDGF protein and binding of the macrophage ligand
to the PDGF cell surface receptor.
The

work

presented

here

with

PDGF-related

proteins

secreted by human vascular endothelial cells provides evidence
of a group of peptides which produce their biological effects
through

the

PDGF

cell

surface

receptor

probably

conformational similarity of the mature proteins.

due

to

The brief

synopsis of growth factors presented above demonstrates that
the peptide growth factors
multiple genes

have evolved into

It seems probable then that there are

other genes and proteins related to PDGF
mitogenic

of

and proteins capable of producing similar

biological activities.

and

families

for

mesenchymal

cells

whic~

in

are chemotactic

addition

to

the

presently identified PDGF A and B chain peptides.
Conditioned media from cultures of Human Umbilical Vein

9

Endothelial (HOVE) cells have been reported to contain factors
which compete with platelet PDGF for binding to the PDGF cell
surface receptor of fibroblasts and demonstrate PDGF-related
biological activity

(DiCorletto, 1984) •

HOVE cells express

both the A and B chain genes of PDGF (Collins et al.,1985;
Collins et al.,1987; Doolitle et al.,1987).

The B chain gene

of PDGF produces a single transcript in HUVE cells of 3.8 kb
(Collins et al., 1985). The HOVE cell PDGF A chain gene is
expressed as three mRNA transcripts of 2.8,2.3 and 1.7 kb,
wi th

the

longest

translated
differs

transcript

thought

(Bonthron et al.,1988).

from A chain transcripts

to

be

the

only

one

The HUVE A chain mRNA
derived

from

neoplastic

glioma cell lines by alternative splicing in which exon six
of the genomic sequence is removed from the HUVE transcript,
resulting in a translated peptide lacking a highly basic 15
amino acid carboxy terminal region found in the glioma peptide
(Collins et al.,1987; Tong et al., 1987).

Since both the A

and B chain genes are expressed, the secreted molecules could
be AB heterodimers or AA or BB homodimers.

The question we

originally asked was what form of PDGF is secreted by human
endothelial cells?
We have investigated the composition and nature of the
PDGF-related

mitoattractant

vascular endothelial cells.

activity

secreted

by

human

PDGF-immunoreactive molecules

were purified from HOVE cell conditioned media by anti-PDGF
IgG affinity chromatography.

Biological- assays

of

these

10

affinity purified proteins in conjunction with immunoblots
using sequence specific anti- A and B chain POGF antibodies
indicate that less than 15% of the PDGF-related molecules
contain sequences which are antigenically related to PDGF A
or B chain.

The major mitoattractant secreted by these cells

appears to be a 36 kd

molecule which is related to platelet

PDGF but is not a product of the PDGF A or B chain gene.
Screening of an expression eDNA library made from the mRNA of
HOVE cells with anti-PDGF antibody has resulted in the cloning

and sequencing of a cDNA which encodes a 38 kd peptide which
our data indicates is the primary source of the PDGF-related
biological activity secreted by HUVE cells.

We have termed

this new mitogen connective Tissue Growth Factor.

11
RESULTS

Identification

and

partial

purification

of

PDGF-related

mitogenic activity trom HUVE cells.
The initial studies of the nature of the Platelet-Derived
Growth Factor related proteins secreted by Human Umbilical
Vein Endothelial

(HOVE)

cells were done to determine the

relative molecular weight

of

the molecules

produced,

amount of the proteins secreted by these cells,

the

and their

specific biological activity.
Endothelial cells were obtained by collagenase perfusion
from the veins of fresh human umbilical cords and cultured in
growth media containing 20% fetal calf serum, basic FGF and
heparin.

The

growth

media

was

removed

from

confluent

cultures, the cells washed and the growth media replaced with
serum-free media containing no other additives.

Aliquots of

this serum-free media were removed periodically and dialyzed
against 1 N acetic acid.
resuspended and
gels.

The proteins were lyophilized,

run on 12% polyacrylamide electrophoresis

The proteins were electroblotted to nitrocellulose and

the membranes immunoblotted using anti-PDGF goat IgG as a
first antibody and rabbit anti-goat IgG alkaline phosphatase
conjugated as a second antibody.

The proteins were visualized

after incubation with a substrate solution. (Fig. 1).

The

results indicated constitutive secretion of several species
of molecules which are immunologically similar to human
platelet PDGF but are of higher molecular weight (36-38 kd)
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Figure 1.

6

18

30

48 PDGF

- 130
- 75

- 50
- 36
- 27
-17
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Figure

1.

constitutive

secretion

of

PDGF-immunoreactive

factors by HOVE cells.

HOVE cells were grown to confluence in 6 well plates. The
growth media was removed, cells washed with PBS and 1 ml of
serum free media was added to each well.

The

media was

removed after conditioning for the period of time indicated
(hours), dialyzed against 1 N acetic acid and lyophilized.
The

samples were then run on 12% PAGE,

nitrocellulose

and

visualized

with

the

electroblotted to
anti-human

PDGF

antibody.
Five nanograms of purified platelet PDGF was run as reference.
positions of MW markers (BioRad) is indicated at right.
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than the expected 30-32 kd of platelet PDGF or the PDGF A or
B chain homodimers.

The concentration of the proteins in the

media increases with time, indicating that the proteins are
being produced by the cells.

The anti-PDGF antibody used in

these experiments was made by immunizing a goat with PDGF
purified to homogeneity from human platelets
1984).

(Grotendorst,

The amino acid composition of the antigen was obtained

and was consistent with human platelet PDGF and a single band
was observed on silver stained polyacrylamide gels.

This

antibody does not cross-react with other growth factors such
as TGF-p, FGF or EGF in immunoblot analysis and is able to
detect less than 500 picograms of dimeric PDGF molecules or
10 nanograms of reduced, monomeric A or B chain peptides on
immunoblots.
The biological activity of the serum-free conditioned
media was analyzed by mitogenic and chemotactic assays.

These

results indicated biological activity in the conditioned media
equivalent

to

15

ng/ml

conditioning time (Fig.

of
2).

platelet

PDGF

after

48

hours

The activity is comparable to

platelet PDGF in that it is both chemotactic and mitogenic for
the fibroblasts used as target cells.
conditioned

media

with

60

~g/ml

Prior incubation of the
of

anti-human

PDGF

IgG

neutralized approximately 30% of the mitogenic and chemotactic
activities.

This is in agreement with previous reports

(DiCorletto,1984).

The mitogenic activity remaining after

antibody neutralization of the PDGF-related fraction is

A
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Figure 2.

Chemotactic and mitogenic assays of HUVE cell

conditioned media and affinity purified PDGF immunoreactive
factors.
A.

Mitogenic assay performed as described using NRK cells

as target cells. PDGF BB is 5 ng/ml.

PDGF AA is 10 ng/ml.

HUVE media is 250 J'l of HUVE cell serum-free conditioned media
(48

hrs)

which

was

dialyzed

against

1

N acetic

acid,

lyophilized, and resuspended in DMEM before addition to test
wells.

Affinity purified fraction is 5

concentrated major pool

~l/ml

of combined,

from Affi-Gel 10 affinity column.

Anti-PDGF IgG or non-Immune IgG (30

~g/ml)

was added to the

samples and incubated 18 hrs at 4°C prior to testing in the
mitogenic assay.

The data points in A and B are the mean of

triplicte samples with a standard deviation of less than 5%.
The experiments were repeated at

least three times with

similar results.
B. Chemotactic assays were performed as described using
3T3 cells as target cells.
10 ngjml.

HUVE media

is

conditioned for 48 hrs.
J.Lljml

of

combined,

affinity column.
described under A.

PDGF BB is 5 ngjml.
serum-free

DMEM,

0.2

PDGF AA is
mg/ml

BSA,

Affinity purified fraction is 2.5

concentrated major pool

from

Affi-Gel

Antibody neutralization is performed as

17

probably due to FGF and the remaining chemotactic activity to
fibronectin,

both

of

endothelial cells.

which

are

secretory

products

of

In these assays and throughout this

project, bacterially produced recombinant PDGF AB, AA and BB
dimeric

molecules

are

used

as

control

standards.

These

molecules offer the advantage of being homogeneously pure,
wi th

no

chance

of

contamination

by

other

growth

present in human platelets (e.g. TGF-p,TGF-a).

factors

In biological

assays conducted periodically in our lab, these recombinant
molecules

produce

activities

identical

to

the

purified

naturally occuring isoforms of PDGF.
The
several

presence
species

in
of

the

HUVE

PDGF

cell

conditioned

immunoreactive

media

molecules

of
was

unexpected, particularly molecules of higher molecular weight
than those of the A and B chain dimeric molecules anticipated

to be produced and secreted by endothelial cells (Collins et
al.,1987;Sitaras et al.,19B7).
done,

we

had

In similar work previously

shown that the non-transformed

BSC-l

monkey

kidney epithelial cell line constitutively secretes PDGF-like
activity into culture media and that 90% of the activity is
neutralized by anti-PDGF IgG.

Immunoblots of the dialyzed

media proteins using the anti-PDGF antibody indicated a single
band which co-migrated on polyacrylamide gels with the PDGF
BB homodimer.

This was consistent with the production of PDGF

B chain mRNA but no A chain mRNA in these cells (Kartha et
al.,1988).
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In order to obtain greater amounts of the PDGF-like
proteins for further analysis, the HOVE cells had to be kept
in media containing 20% fetal calf serum, since these cells
begin to die after 24 hours in serum-free or low serum media.
The PDGF immunoreactive proteins were partially purified from
the serum containing media by use of an antibody affinity
column made with the anti-human PDGF IgG and an Affi-Gel 10
support (BioRad).

When aliquots of the partially purified

proteins were assayed for chemotactic and mitogenic activity,
all

biological

activity

could

be

neutralized

by

prior

incubation of the proteins with the anti-human PDGF antibody
(Fig. 2).

This indicated that the only biologically active

molecules present in the partially purified media proteins
were PDGF immunorelated molecules.

Aliquots of the partially

purified proteins were immunoblatted using the same anti-PDGF
antibody and the data indicated the presence of both the
higher MW molecules observed in the serum-free conditioned
media

and

(Fig.3).

immunoreactive proteins

in

the

30-32

kd

range

The major species secreted migrated at 36 kd on

acrylamide gels and represented at least 50% of the total
immunoreactive protein.

The peptides which comigrated with

purified platelet PDGF and synthetic A and B chain dimeric
standards represented less than 15% of the total
immunoreactive protein.
purified

PDGF

blocked

Prior incubation of the antibody with
antibody

binding

to

all

of

molecules, indicating shared antigenic determinants with

the
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Figure 3.
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Figure

3.

Immunoblot

of

HUVE

cell

secreted

PDGF-related

factors.
Proteins

were

electroblotted

to

run

a

on

a

12%

nitrocellulose

polyacrylamide

gel

membrane

the

and

immunoreactive factors visualized with anti-human PDGF IgG as
described under Experimental

Procedures.

Lane

1,

5

J.l.l

of

affinity purified HUVE cell secreted proteins. Lane 2, 10 ng
of synthetic AA homodimer (top band) and 10 ng of BB homodimer
(lower band).
proteins.

Lane 3, 50 J.l.l of reduced HUVE affinity purified

Lane

4,

5

J.l.l

of HUVE

affinity purified HUVE

proteins but with anti-human PDGF antibody blocked with 300
ng of PDGF.

Lane 5, Control column of 10 J.l.l of anti-PDGF

Affi-Gel 10 affinity purified protein fraction
which was not conditioned by cells.

from media
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dimeric platelet PDGF (Fig.3,lane 4).

In order to insure that

none of the antibody binding molecules detected on immunoblots
was derived from fetal calf serum or other additives in the
culture media, a new, unused antibody affinity column was made
and media which was never conditioned by cells was incubated
at 37 C for two days and processed exactly as the conditioned
media.

No PDGF-immunoreactive molecules were detected in the

fractions from this column by immunoblot (Fig. 3,lane 5) and
no biological activity was detected (data not shown).
When platelet PDGF or the recombinant dimers were reduced
with 100

roM

dithiothreitol and boiled for 5 minutes in the

presence of SDS, monomeric A chain (17 kd) and B chain (14 kd)
peptides were observed on immunoblots.
molecules in

100

mM

DTT

Treating the HUVE

sample buffer and boiling for

5

minutes resulted in slower migration of the major portion of
the immunoreactive molecules on polyacrylamide gels (Fig. 3).
Most of the immunoreactive molecules migrated at 38-39 kd and
less intense bands were observed at 25 kd and 14 kd.

It is

necessary to run at least 10 times as much reduced protein as
non reduced in order to detect the reduced proteins.

This is

consistent with the affinity of our antibody for monomeric
forms of the PDGF A and B chain peptides.

Since our antibody

was produced against dimeric platelet PDGF, a lower affinity
to monomeric forms is not unexpected.
Our

preliminary

data

indicated

that

HUVE

cells

constitutively secrete several molecules ~ which share some

22

antigenic properties with human platelet PDGF and exhibit
similar biological activities.

lnununoblotting procedures with

both non-reduced and reduced affinity purified protein samples
indicated

that

the

major

immunoreactive

protein

in

the

biologically active samples was a monomeric molecule which
migrated at approximately 38 kd.
In addition to these peptides which constitute the major
portion of the PDGF immunoreactive molecules, species which
migrated at higher MW were observed in the first few fractions
eluted

from

the

anti-PDGF affinity column.

In order to

determine which of all these bands on the immunoblots were
PDGF-specific, and possibly which were A or B chain related,
a protein mixture was made by taking an aliquot of each of the
fractions eluted from the anti-PDGF IgG affinity column used
to purify these proteins from HUVE cell conditioned media.
An immunoblot was made with four aliquots of this mixture and
the

membrane

was

cut

into

four

sections

and

a

section

incubated with anti-PDGF IgG previously blocked with one of
the three isoforms of PDGF and one section with unblocked
antibody

(Fig.

4).

We

found that each of the different

isoforms of PDGF block binding of the antibody to the major
secretory products
degree.

of

the

endothelial

cells

to

an

equal

The higher molecular weight proteins were unaffected

by the antibody blocking and are probably due to nonspecific
binding

of

the

antibody.

The

PDGF

isoforms

also

block

antibody binding to each other (i.e. AA dimers block binding
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Figure 4.

Immunoblot of affinity purified HOVE proteins

demonstrating anti-PDGF antibody blocking with the isoforms
of PDGF.

Lanes 1 and 2 anti-PDGF antibody previously incubated

with recombinant PDGF AA homodimer.

Lane 1 contains 1

aliquot of HOVE affinity purified proteins.
20

~l

Lane 2 contains

nanograms of PDGF AA homodimer.
Lanes 3 and 4, anti-PDGF antibody previously incubated

with recombinant PDGF AB heterodimer.

Lane 3 contains 1

aliquot of HOVE affinity purified proteins.

~l

Lane 4 contains

10 nanograms of PDGF AB heterodimer.

Lanes 5 and 6, anti-PDGF antibody previously incubated
with recombinant PDGF BB homodimer.
aliquot of

Lane 5 contains 1

HOVE affinity purified proteins.

~l

Lane 6 contains

10 nanograms of PDGF BB homodimer.

Lanes 7 and 8, anti-PDGF antibody.

Lane 7 contains 1

aliquot of HOVE affinity purified proteins.
10 nanograms of PDGF AB heterodimer.

~l

Lane 8 contains

25

to BB dimers).

Therefore,

the major IgG clones

in this

polyclonal antibody appear to be against similar epitopes on
the PDGF isoforms and the endothelial cell molecules.
From this data alone we were not able to determine which
of the peptides in the nonreduced lane corresponded to the 38
kd peptide in the reduced samples, representing the majority
of the immunoreactive protein, and which produced the 25 and
14 kd peptides on our immunoblots.
we

labeled

cultures

of

HUVE

In order to analyze this,

cells

with

35

s - cysteine and

affinity purified the anti-PDGF immunoreactive peptides from
the conditioned media.

Equal aliquots of the labeled affinity

purified proteins were run both reduced and non-reduced on
polyacrylamide gels and electroblotted to nitrocellulose and
the membrane processed as for immunoblots using the anti-PDGF
antibody.

The immunoblots were then autoradiographed (Fig.5).

Transmission scanning of the

lanes

of the

autoradiograph

determined that the 36 kd band in the nonreduced lane and the
38 kd band in the reduced lane have equivalent intensity.
This indicates that the 36 kd molecule is monomeric and shifts
to the apparent higher molecular weight due to unfolding of
the molecule upon reduction of intramolecular disulfide bonds.
There was still a question as to whether these higher
molecular

weight

PDGF

immunorelated

proteins

CQuld

be

monomeric precursor forms of PDGF A or B chain peptides which
were

being

secreted

by

endothelial

cells

processed by proteolytic enzymes to the

30~32

without

being

kd size as is
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Figure 5.
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Figure

5.

Autoradioqraph

and

immunoblot

of

35

s - cys teine

labeled HUVE cell secreted proteins.
Confluent cultures of HUVE cells were labeled for 22
hours

in cysteine-free DMEM containing 250

cysteine.

The

labeled

affinity

purified

from

PDGF-inununoreactive
the

conditioned

~Ci/ml

of

proteins

media

and

35

S_

were
equal

aliquots of the proteins run on 12% polyacrylamide gels.

The

proteins

the

were

electroblotted

to

nitrocellulose

membranes processed as for immunoblots.

and

The immunoblots were

then autoradiographed.
Side A is autoradiograph of immunoblot shown on Side B.
Lane 1. 10

~l

aliquot of labeled affinity purified

proteins,nonreduced.
Lane 2. 10

~l

aliquot of labeled affinity purified

proteins,reduced.
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the case for other cell types studied (Kartha et al.,1988).
Since the RNA message for both the A and B chains of PDGF is
expressed in HOVE cells, we wanted to determine which of the
immunorelated molecules were A chain or B chain peptides and
which, if any, were not products of the A or B chain genes.
We

have produced a

series of antibodies

in goats to

synthetic peptides of 30 amino acid length which represent
sequences in the amino and carboxy terminal regions of the
processed PDGF A and B chain peptides.

These antibodies are

specific for the reduced, monomeric A and B chain peptides and
do not cross react when tested on immunoblots with the reduced
recombinant AA, SB and AB dimers.

The peptide antibodies used

in these experiments are specific for the amino (residues 79107)

and

carboxy

(residues

161-189)

ends

of

the

mature

processed B chain peptide of platelet PDGF and the amino end
of the processed A chain molecule (residues 92-119) and the
carboxy end of the short (endothelial)

form of the A chain

molecule (residues 167-193 + DVR; Collins et al. , 1987).

When

100 nanograms of the affinity purified HOVE cell PDGF-like
proteins are reduced and immunoblotted using the anti amino
terminal A chain antibody, we detect a single band of peptides
at 17 kd (Fig. 6).

comparison with 10 nanograms of reduced

recombinant A chain peptides on the same immunoblot indicates
that only 10 nanograms of proteins containing the amino
terminal sequence are present in 100 nanograms of HUVE cell
molecules.

Similar results were obtained using the antibody
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Figure 6.
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Figure 6. Immunoblot of HOVE cell secreted proteins using A
and B chain peptide antibodies.

A. Primary antibody is anti-human POGF IgG. Lane 1, 10
ng of HOVE affinity purified media proteins, non-reduced. Lane
2, 100 ng of HOVE affinity purified proteins, reduced.

B. Primary antibody is anti amino terminal A chain serum
for lanes 1 and 2 and the antibody blocked with the peptide
Lanes 1 and 3 100 ng of HUVE

antigen for lanes 3 and 4.

purified media protein, reduced.

Lanes 2 and 4, 10 ng of AA

short form homodimer, reduced.

c.

Primary antibody is anti carboxy terminal A chain

serum for lanes 1 and 2 and the antibody blocked with the
peptide antigen for lanes 3 and 4.

Lanes 1 and 3, 100 ng of

HOVE purified media proteins, reduced.
of AA

Lanes 2 and 4, 10 ng

homodimer, reduced.

D. Primary antibody is anti amino terminal B chain serum
for lanes 1 and 2 and the antibody blocked with the peptide
antigen for lanes 3 and 4.

Lanes 1 and 3 and 200 ng of HOVE

purified media proteins, reduced. Lanes 2 and 4 are 20 ng of
BB homodimer, reduced.
E.

Primary antibody is anti carboxy terminal

B chain

serum for lanes 1 and 2 and the antibody blocked with the
peptide antigen for lanes 3 and 4.

Lanes 1 and 3, 100 ng of

HOVE purified media proteins, reduced. Lanes 2 and 4 are 20
ng of BB homodimer, reduced.
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specific for the carboxy terminal of the PDGF A chain (Fig.
6).

The data from these two antibodies indicated that of the

total PDGF immunorelated molecules secreted by HUVE cells,
only about 10% contained sequences found in the PDGF A chain
amino or carboxy terminal regions.

The antibody specific for

the 30 amino acid sequence in the amino terminal of the PDGF
B chain peptide did not detect any molecules in 200 nanograms
of reduced endothelial cell proteins.

This antibody is our

least sensitive and it may be that we are not able to detect
the small amount of PDGF B chain molecules present.
chain

carboxy

terminal

peptide

antibody

detects

The B
reduced

molecules at 25 kd and at 14 kd in 100 nanograms of HUVE cell
proteins.

Comparison

with

20

nanograms

of

reduced

BB

homodimer run as a standard on the same blot indicates that
about

5%

of

the

endothelial

cell

PDGF

contain PDGF B chain amino acid sequences.

related

molecules

The 14 kd molecule

is probably reduced B chain which has been proteolytically
processed.

The 25 kd molecule may be reduced 50 kd B chain

precursor molecule, a small amount of which is found in the
conditioned media.
15%

These data indicate that approximately

of the PDGF immunoreactive molecules secreted by HOVE

cells contain sequences of the mature PDGF A and B chain
molecules.

The remaining 85% of this biologically active

protein fraction is not related to the PDGF peptides.
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Major chemotactic and mitoqenic activity is produced by 36 kd
peptide and not POGP paptides.
In order to determine if the chemotactic and mitogenic
activities observed in the partially purified media proteins
were the result of the proteins containing the PDGF A and B
chain peptides or were the result of molecules which do not
contain these sequences, biological assays were performed with
serial dilutions of the affinity purified media proteins and
serial dilutions of recombinant PDGF AA and BB homodimers and
the AB heterodimer.

Sufficient quantities of the samples were

prepared to perform several mitogenic and chemotactic assays
and immunoblots with aliquots of each dilution.

The mitogenic

activity of the HUVE affinity purified factors observed was
comparable to the activity elicited by all three recombinant
PDGF dimers.

The chemotactic activity was comparable to the

AB heterodimer, producing less response than the BB homodimer
and

greater

biological

response
activity

than
of

the

the

AA

homodimer.

samples

was

When

compared

the
with

immunoblots of equivalent amounts of the same samples, no A
chain nor B chain molecules were detected in the test samples
(Fig.

7).

As

an

example,

at

20

ng/ml

of

either

the

recombinant PDGF isoforms or the HUVE cell molecules,

the

biological activity elicited from the target cells was at or
near maximum, but the immunoblot of equal aliquots of these
same samples show that no PDGF A or B chain peptides were
detected in the HUVE cell molecule

samples.~

The detection
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Figure

7.

Biological

assays

and

immunoblots

of

serial

dilutions of HUVE cell affinity purified media proteins and
recombinant PDGF standards.
Mitogenic assay

(A)

and chemotactic assay

described with NIH 3T3 cells.

(B)

performed as

The test samples

in both

biological assays and the immunoblot are identical aliquots
of the same sample.

Data points are the mean of three samples

and the standard deviation is less than 10%.
Fig. C, Immunoblot A, primary antibody is anti-human
PDGF IgG.

Lane 1, 20 ng HUVE purified media proteins.

Lane 2, 20 ng AB heterodimer.
Immunoblot B. Primary antibody is anti amino terminal
A chain serum.
Lane 1, 20 ng of HOVE purified media proteins, reduced.
Lane 2, 20 ng AA homodimer, reduced. Lane 3, 1.25 ng

AA homodimer, reduced.
Immunoblot C. Primary antibody is anti carboxy terminal
B chain serum.
Lane 1, 20 ng HUVE purified media proteins, reduced.

Lane 2, 20 ng BS homodimer, reduced.
Lane 3, 2.5 ng BB homodimer, reduced.
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level on this blot with these peptide antibodies was less than
1.25

nanograms

for

A

chain

peptides

nanograms for B chain peptides.
that

of

molecules

the

total

secreted

fraction
by

HUVE

and

less

than

2.5

As shown above, we estimate
of

anti-PDGF

cells,

less

immunoreactive

than

15%

contain

sequences of the PDGF A and B chain gene products.

This

being the case, the biological activity produced by the test
samples in these dilution assays cannot be accounted for by
PDGF A or B chain containing molecules.
indicated

that

the

36-39

kd

These data strongly

PDGF-immunoreactive

protein

species present in these samples were biologically active.
In order to sUbstantiate the binding of the endothelial
cell molecules to the PDGF cell surface receptors, competitive
receptor binding assays were performed.

Since immunoblots of

the affinity purified endothelial cell proteins indicated the
presence of multiple PDGF-related molecules, 1~I-Iabeled PDGF
competition assays could not be used since this would not
indicate which molecules in this mixture were competing for
binding of the labeled PDGF for the receptors on the target
cells.

Because

the

isoforms

of

PDGF

and

the

maj or

PDGF

immunorelated proteins secreted by HUVE cells are of different
molecular

weights,

we

were

able

binding competition on immunoblots.
anti-PDGF

immunoreactive

peptides

to

demonstrate

receptor

Direct binding of the
to

NIH

3T3

cells

was

demonstrated by incubating monolayers of the 3T3 fibroblasts
with the anti-PDGF affinity purified proteins (10 ngjml) for

36

2 hours at 4 C.

the

cell

Bound peptides were released by washing of

layer with

1

N

acetic

acid

and

quantitated

immunoblot analysis using anti-PDGF IgG (Fig. 8).

by

The data

show that the 36 kd immunoreactive peptide bound to the cell
surface of NIH 3T3

cells.

This binding could be competed by

increasing concentrations of recombinant PDGF BB added to the
binding media.

These data suggest that the CTGF peptide binds

to specific cell surface receptors on NIH 3T3 cell and that
PDGF BB can compete with this binding.
The data which we now had gave strong evidence that the
PDGF related proteins from HUVE cells were able to bind the
PDGF cell surface receptor of mesenchymal cells and elicit
both

chemotactic and mitogenic activity equivalent to the

isoforms of PDGF.

The biological activity was being produced

by proteins which did not contain sequences present in the

amino or carboxy terminals of the PDGF A or B chain peptides.
The presence of three predominant bands on immunoblots and the
fact that PDGF A and B chain peptides constituted 15% of the
biologically active molecules complicated efforts to purify
the biologically active molecules which were not A or B chain
related.

Figure 8.

123456789
HUVE

PDGF>
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Figure 8.

PDGF cell surface receptor binding competition

assay with NIH 3T3 cells and HUVE affinity purified proteins
competing with recombinant PDGF BB homodimer.
Lane 1 contains 10 nanograms of HOVE affinity purified
proteins and lane 9 contains 10 nanograms of recombinant

PDGF BB homodimer.
Lanes 2 through 8 are proteins dissociated in one well
of a 24 well plate from the cell surface of NIH 3T3 cells with

acetic acid. The cells in each well were incubated for 2 hours
at 4 C with serum-free DMEM containing 10 ng of affinity

purified

proteins

from

varying

concentrations

HUVE
of

cell

conditioned

recombinant

PDGF

media

BB.

and

The

concentration of PDGF in lane 2 is 300 ng; lane 3 is 150 ngi
lane 4 is 75 ng; lane 5 is 37.5 ng; lane 6 is 18.75 ng; lane
7 is 9.4 ng and lane 8 has no addition of PDGF.
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Cloning and saquencinq of the eDNA for connective Tissue
Growth Factor.

In order to

further

characterize

these

PDGF

related

molecules, we used the anti-PDGF antibody to screen an HOVE
cell eDNA library made in the expression vector lambda gtll
(a gift

from T.

Collins,

Harvard).

Clone selection

is

accomplished by the binding of the antibody to fusion proteins
which are part p-galactosidase from the vector and part human
endothelial cell protein from the HOVE eDNA inserts.
500,000 recombinant clones were screened.

Over

Several clones

which gave strong signals with the anti-PDGF antibody in the
screening process were purified and subcloned into the M13
phage vector and partial sequence data obtained by single
stranded

DNA

sequencing.

A search

of

the

GenBank

DNA

sequence data system indicated that two of the clones picked
contained fragments of the PDGF B chain cDNA open reading
frame sequence.

One of these clones was a 1.8 kb fragment

similar to one previously isolated by Collins,et ale
using a c-sis eDNA probe.

(1985)

This result established that the

library screening process with the anti-PDGF antibody was an
effective method for identifying eDNA clones producing fusion
proteins containing PDGF related antigens.

A third clone of

500 bp was completely sequenced and no match was found in a
homology search of all nucleotide and amino acid sequences in
GenBank.

This

clone was designated DB60.

In order to

demonstrate specificity of the anti-PDGF antibody binding to

40

the

fusion protein produced by clone DB60,

the phage was

plated on a 100 mm plate and the fusion protein induced by
placing two pieces of IPTG soaked nitrocellulose on the plate
and processed in the same manner as for the library screening.
One filter was incubated with the anti-PDGF antibody and the
other was incubated
blocked

by

incubation

secreted proteins.
by

the

with the anti-PDGF antibody previously

with

affinity

HUVE

purified

cell

Antibody binding to the protein produced

clone DB60 was completely blocked by the affinity

purified proteins (Fig.9).

This antibody blocking provides'

evidence that the HUVE cell affinity purified proteins seen
on immunoblots are the same as the endothelial cell portion
of the fusion protein produced by clone DB60.

Clone OB60 was

subcloned into Bluescript phagemid (stratagene).

A 32 P -l a beled

probe was made of DB60 and used on a Northern blot of 20
of total RNA isolated from HUVE cells (Fig.

10).

~g

The blot

indicated probe hybridization with an mRNA of 2.4 kilobases,
which is a message of sufficient size to produce the proteins

in the 38 kd molecular weight range seen on immunoblots of the
reduced affinity purified proteins.

The DB60 clone was used

to rescreen the HUVE cell cDNA lambda gt11 library and the
largest clone isolated contained a 2100 base pair insert.

A

probe made with the 500 bp fragment in clone DB60 hybridized
to

the Eco RI

insert

in the

new clone,

labeled DB60R32,

indicating that it was a larger eDNA clone containing
sequences homologous to the 500 bp sequence in clone DB60

Figure 9.

1

2
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Figure 10.

Northern blot of total cellular RNA demonstrating
hybridization of CTGF gene probe.

The hybridization probe for first lane was clone DB60, the
500 bp clone selected from the gtll library. Probe for

all other lanes was clone DB60R32,the 2100 bp eDNA of
the CTGF gene.

Lane 1.

2·0 J..I.g of total RNA from HUVE cells.

Lane 2.

20 J..I.9 of total RNA from HUVE cells

Lane 3.

20 J..I.g of total RNA from human fibroblasts.

Lane 4.

20

~q

of total RNA from human fibroblasts

stimulated with TGF-beta for five hours.
Lane 5. 20 J.Lg total RNA from TGF-beta stimulated RPE

cells.
Lane 6.

20

Lane 7.

20 J..I.g total RNA from human macrophages.

~g

total RNA from human neutrophils.
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which was picked with the anti-PDGF antibody (Fig. 11).

The

2100 bp clone DB60R32 was also used as a probe in Northerns
of total RNA from HOVE cells and hybridized with a single 2.4
kb message (Fig. 10).

Work previously done in this lab had

shown that primary cultures of human foreskin fibroblasts
(Soma

and

epithelial

Grotendorst,1989)
(RPE)

cells

and

human

(Campochiaro

et

retinal

pigment

al.,1989),

upon

stimulation with TGF-beta, secrete into culture media PDGFrelated biological activi ty .

In both cases,

the secreted

PDGF-related proteins produce a pattern similar to the HUVE
peptides on immunoblots using the anti-PDGF antibody with the
major protein species in the 36-39 kd MW range.

Fibroblasts

which were not incubated with TGF-/3 did not secrete these
peptides.

Northern blots of 20

stimulated fibroblasts

~g

(5 hours)

of total RNA from TGF-beta
and RPE cells

(24 hours)

using the DB60R32 clone as a probe demonstrated hybridization
to a 2.4 kb message.

Human fibroblasts which were not treated

with TGF-/3 did not express this mRNA (Fig. 10).

Pencevand

Grotendorst (1987) had demonstrated the secretion of the 16
kd MDGF peptide by endotoxin stimulated human macrophages and
shown this to be the primary protein species producing the
PDGF-related biological activity
media from these cells.

found

in the conditioned

In order to determine if there was

any relationship between MDGF and CTGF or if CTGF were induced
in leucocytes, 20

~g

of total RNA from stimulated macrophages

and neutrophils were run on agarose gels and blotted.

Probing
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Figure 11.
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Figure 11.

Southern blot showing hybridization of Eco RI

fragment of clone DB60 hybridizing to immobilized 2100 bp
fragment of clone DB60R32.
The 2100 bp Eco RI insert from the HUVE cDNA lambda gtl1

expression

library

DB60 I the clone

was

picked

by

hybridization

to

originally picked with anti-PDGF antibody.

insert was subcloned into Bluescript phagemids KS
Lanes 1 and 2 are aliquots of
(lane 1)

clone

and cut with Eco RI

The

and SK.

Bluescript KS/DB60R32 DNA uncut
(lane 2).

Lanes 3 and 4 are

aliquots of Bluescript SK/DB60R32 DNA uncut (lane 3) and cut
(lane

4)

wi th Eco RI.

The

DNA was

run

on

a

1%

agarose

gel,transferred to nitrocellulose membrane and probed with the
500 bp Eco RI insert from clone DB60. This demonstrated that

the inserts of cDNA contained regions of homologous sequence.
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the blots with DB60R32 indicated that the CTGF message is not
expressed or is not expressed in abundance to be detected on
total

RNA

blots

as

would

be

expected

from

the

high

concentrations of active peptides found in conditioned media
(Fig. 10).
In order to determine the size of the translation product

of the DB6.0R32 eDNA clone, the 2100 bp insert was cloned into

the Bluescript vector and transcribed in vitro using the T7
polymerase promoter and the mRNA transcript was translated in
vitro using a

rabbit reticulocyte lysate method with

cysteine for labeling.
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S_

Aliquots of the translation reaction

were run reduced with 50 roM DTT on 12% polyacrylamide gels
(Fig. 12).

The data indicate a protein product which migrates

at an apparent molecular weight of 38 kd and co-migrates with
the reduced affinity purified proteins from the HUVE cell
conditioned media.
The

2100

initially by

bp

insert

of

subcloning of

clone
Pst

I

DB60R32
and

Kpn

was
I

sequenced

restriction

fragments into Bluescript and using double stranded dideoxy
methods (Fig. 13).
1076 base pairs.

This determined an open reading frame of
An Eco RI/Kpn I

fragment containing the

entire open reading frame was inserted into M13 mp18 and M13
mp19 and both strands of the DNA were sequenced with single
stranded dideoxy methods by primer extension using both GTP
and the GTP analog ITP.

The cDNA nucleotide sequence

49

Figure 12.

1

2

3
-50
-36
-27
-17

so
Figure

In

12.

vitro

translation

product

eDNA

of

clone

DB60R32.

Lanes 1 and 2 are an immunoblot using the anti-human PDGF
antibody with (1) 10 ng nonreduced and (2) 100 ng reduced of
HUVE cell affinity purified proteins from conditioned media.
Lane

3

is

an

autoradiograph

reticulocyte

in

incorporated

1

vitro
~g

of

of

4

translation
RNA

J.£l

of

a

reaction

transcript

from

50

J.£l

rabbit

which
an

in

vitro

transcription reaction using the 2100 bp clone DB60R32

in

Bluescript phagemid. Autoradiograph was exposed for 24 hours.

CLONE ORIENTAnON AND SEQUENCING MAP FOR
CONNECTIVE TISSUE GROWTH FACTOR cDNA1S
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Figure 13. Sequence map of CTGF eDNA clone.
Top line represents the 2075 bp DB60R32 clone containing
open reading frame of CTGF.

Restriction enzyme sites used in

sUbcloning are indicated as are the ATG initiation site and
the TGA termination codon.
from

the

indicated.

HUVE

cDNA

The position of clone 0860, picked

library with

anti-PDGF

antibody,

is

Solid squares indicate locations of primers

used in sequencing.

Solid arrows indicate reads of single

stranded sequencing and broken arrows indicates region in 3'
end

for

available.

which

only

double

stranded

sequencing

data

is
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indicates an open reading frame of 1047 bp which encodes a
38,000 MW protein (Fig.14).

This protein has a 45% overall

homology with the translation product of the v-src-inducible
chicken embryo fibroblast CEF-IO mRNA (Simmons et al.,1989)
(Fig. 15).

CCCGGCCGACAGCCCCGAGAeGACAGCCCGGCGCGTCCCGGTCCCCACCTCCGACCACCGCCAGCGCTCCAGGCCCCGCGCTCCCCGCTCGCCGCCACC

99

GCGCCCTCCGCTCCGCCCGCAGTGCCAACC ATG ACC Gee Gec AGT ATG GGC eee GTC CGe GTC Gee TTe GTG GTC CTC eTC

180

Met Thr Ala Ala Ser Met Gly Pro Val Arg val Ala PIle VaL Val Leu Leu

17

Gee CTe TGC AGe eGG CCG Gec GTC GGe CAG AAe TGC AGe GGG CCG TGC eGG TGe eeG GAe GAG COG GeG CCG eGe

255

Ala Leu Cys Ser Arg Pro Ale Val Gly Gin Asn Cys Ser ely Pro Cya Arg Cys Pro Asp Glu Pro Ala Pro Art

42

TGC eeG GCG GGe GTG AGe eTC GTG eTG GAC GGe TGe GGC TGe TGC CGe GTC TGC Gec AAG CAG eTG GGe GAG CTG

330

Cys Pro Ale lily val ser L. . val Leu

asp Gly

Cys Gly Cys Cya Arg Val Cys Ala Lys Gin Leu Gly Glu Leu

67

TGC Ace GAG eGe GAe eec TGC GAC eeG CAC AAG GGe eTC TTe TGT GAC TTC GGe Tec ceG Gee AAC CGe AAG ATC

405

Asp Pro His Lys Sly Leu Phe Cys Asp PIle Gly Ser Pro At. AM Arg Lya He

92

Cys Thr Glu Are Asp Pro

era

GGe GTG TGC Ace Gec AAA GAT GGT GCT cec TGC ATC TTC GGT GGT ACG GTG TAe CGe AGe GGA GAG Tee TTe CAG

480

Gty VaL cy. Thr Ala Lya Asp eLy Ala Pro Cys lie PIle ely ely Thr Val Tyr Arg Ser ely Slu ser PIle Gln

117

AGe AGC TGC AlG TAe CAG TGC ACG TGC CTG GAe GGG GeG GTG GGe TGC ATG ecc eTG TGC AGe ATG GAC GTT CGT
Ser ser Cys L)'S Tyr Gin C)'S Thr Cys Leu Asp Gly Al. VaL GLV Cya Ret Pro Leu Cys Ser Met Asp Val Arg

555
149

CTG eec AGC eeT GAC TGC eee TTC eeG AGG AGG GTC AAG CTG CCC GGG AAA TGC TGC GAG GAG TGG GTG TGT GAC

630

Leu Pro Ser Pro Asp Cya Pro ..... Pro Arg Art! Val Lya Lal Pro Gly Lys Cya Cys Glu stu Trp Val Cya Asp

167

GAG ecc AAG GAC eM ACe GTG GTT GGG CCT Gce CTC GeG GeT TAC eGA. CTG GAA GAC ACG TTT GGC eeA GAC teA . 705
Gtu Pro Lys Asp Gin Tbr Val Val Gly Pro Ala Ley Ala Ala Tn Ara Leu Glu Asp Thr Phe Gl! Pro Asp Pro
192
ACT ATG ATT AGA GCe AAC TGC CTG GTe CAG Ace lCA GAG TGG AGe Gec TGT Tee AAG Ace TGT GGG ATG GGC ATC
Thr Met lie Ani Ala

A!n

780

Cys Leu VaL Gln Thr Thr GLu Trp Ser Ala Cys Ser Lys Thr Cys Gly Met Gly Ile

217

Tce ACC CGG GTT Ace AlT GAt Ale Gee Tce TGC AGG CTA GAG AAG CAG AGC CGe eTG TGC ATG GTe AGG eey TGC

855

ser Thr Ara Val Thr- Asn Aap AM Al. Ser Cya AF'II Leu Glu Lys Gln Ser Ara Leu Cys Met Val Arv Pro Cys

Z4Z

GAA GCT GAt CTG GAA GAG AAe ATT AAG AAG GGe AlA AAG TGC ATC CGT ACT eec AAA ATC Tee AAG eCT ATC AAG

930

Glu Ala Asp Leu Glu slu Asn He Lys lys Sly Lys Lya Cys He AI'8 Th.. Pro Lya He Ser L,.. Pro He Lys

267

TTT GAG CTT TeT GGe TGC ACC AGC ATG MG AtA TAC eGA GeT AAA lTC TGT GGA GTA TGT ACC GAC GGC eGA TGC 1005
Phe Glu Leu Ser Gly Cys Thr ser Met Lys Thr lyr Are Ala Lys PIle Cys Gly val cya Thr A8p Gly Ira Cya
292
TGC Ace CCC CAt AGA Ace ACC Ace eTG CCG GTG GAG TTC AAG TGC eCl GAt GGC GAG GTC ATG lAG AAG AAC ATG 1080
Cys

Thr Pro His Art Thr Thr Thr Leu Pro Val Glu PIle Lya Cys Pro Asp Gly Glu VaL Met LYII Lya Am Met

317

ATG TTC ATe AAG Ace TGT Gee TCC CAT TAC MC TGT eee GGA GAC MT GAt ATt TTT GAl TCG CTG TAC TAC AGG 1155
Met PM He lya Thr Cys Ale Cya His Tyr A8n Cys Pro Gly Asp Asn Asp Jle Phe Glu Ser L. . Tyr Tyr Art

342

MG ATG TAC GGA GAt ATG GCA TGA. AGCCAGAGAGTGAGAGACATTAACTCATTAGACTGGAACTTGAACTGATTCACATCTCATTTTTCC 1245
Lys Met Tyr Gly Asp Met: Ala Tertii

GTAAAAATGATTTCAGTAGCACAAGTTATTTAAATCTGTTTTTCTAACTGGGGGAAAAGATTCeCACCCAATTCAAAACATTGTGCCATGTCAAACAAA
TAGTCTATCTTCCCCAGACACTGGTTTGAAGAATGTTAAGACTTGACAGTGGAACTACATTAGTACACAGCACCAGAATGTATATTAAGGTGTGGCTTT
AGGAGCAGTGGGAGGGTACCGGCCCGGTTAGTATCATCAGATCGACTCTTATACGAGTAATATGCCTGCTATTTGAAGTGTAATTGAGAAGGAAAATTT
TAGCGTGCTCACTGACCTGCCTGTAGCceCAGTGACAGCTAGGATGTGCATTCTCCAGCCATCAAGAGACTGAGTCAAGTTGTTeCTTAAGTCAGAACA
GCAGACTCAGCTCTGACATTCTGATTCGAATGACACTGTTCAGGAATCGGAATCCTGTCGATTAGACTGGACAGCTTGTGGCAAGTGAATTTGCeTGTA
ACAAGCCAGATTTTTTAAAA-IIIATATTGTAAATATTGTGTGTGTGTGTGTGTGTGTATATATATATATATATGTACAGTTATCTAAGTTAATTTAAAG
TTGTTTGTGCCTTTTTATTTTTGTTTTTAATGCTTTGATATTTCAATGTTAGCCTCAATTTCTGAACACCATAGGTAGAATGTAAAGCTTGTCTGATeG
TTCAAAGCATGAAATGGATACTTATATGGAAATTCTGCTCAGATAGAATGACAGTCCGTCAAAACAGATTGTTTGCAAAGGGGAGGCATCAGTGTCTTG
GCAGGCTGATTTCTAGGTAGGAAATGTGGTAGCTCACG*

349

1344
1443
1542
1641
1740
1839
1938
2037
2075
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Figure 14. Nucleotide sequence and amino acid translation of
connective

Tissue

Growth Factor eDNA

from

human vascular

endothelial cells.
The open reading frame for the CTGF protein extends from

the ATG initiation site at nucleotide 130 to the TGA site at
1177.

The possible glycosylation sites at asparagines 28 and

225 are underlined.
is boxed.
underlined.

The putative alternative splicing region

The 3' region contains three ATTTA sites which are
The Genbank accession number for this CTGF eDNA

sequence is M36965.

COMPARISON OF CTGF AND CEF-10 PREDICTED PEPTIDE SEQUENCES
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Figure

15.

comparison

of

amino

acid

sequences

of

the

translated eDNA for Connective Tissue Growth Factor and the
CEF-10 mRNA translation product.
The translated eDNA for human CTGF and avian CEF-IO have
a

45% overall homology and a

52% homology if the putative

alternative splicing region is deleted. This region is between

amino acids 171 (aspartic acid) and 199 (cysteine) in the CTGF
sequence.

Homologous regions are shaded and aligned cysteine

residues are indicated with an asterisk.
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DISCUSSION

The

data

presented

here

indicate

that

the

major

connective tissue mitoattractant secreted by HUVE cells is a
38 kd monomeric molecule which is antigenically related to the

dimeric platelet PDGF and competes with PDGF for binding to
the surface of NIH 3T3 cells, but is not a product of the PDGF
A or B chain genes. Our data indicate that

HUVE cells also

secrete both PDGF A and B chain molecules, but at much lower
concentrations than the

38

kd

monomer

and

these

peptides

contribute only a minor fraction of the total chemotactic and
mitogenic activity secreted by these cells.

In the biological

assays performed with the affinity purified proteins from HUVE
media, biological activity equivalent to 20 ng/ml of PDGF was
obtained at low concentrations of the CTGF molecule where no
detectable (less than 2 ng) PDGF A or B chain molecules were
present.
incubation

All biological activity could be removed by prior

of these

samples with

the

anti-PDGF

antibody.

Because all three isomeric forms of the PDGF dimers blocked
antibody binding to the CTGF molecule,

it is evident that

there are some common antigenic determinants shared among
these proteins.

The anti-PDGF antibody has high affinity to

the nonreduced forms of the PDGF isomers and the CTGF molecule
and ten-fold
peptides.

less affinity to the reduced
The

PDGF

A

and

biologically active peptides.

B

chain

forms

monomers

of these
are

not

This suggests that there is a

similar shape and structure between the dimeric PDGF isomers
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and the CTGF molecule and that this conformational similarity
results in the formation of common antigenic epitopes and the
receptor binding sites of these molecules.
The sequence of the eDNA for CTGF indicates an open
reading frame of 1047 nucleotides with an initiation site at
130 and a TGA termination site at position 1177

(Fig. 14).

The ATG codon at position 130 and another at position 145 fit
the concensus sequence for strong translation initiation sites
(Kozak, 1984)

and it is assumed that the first ATG is the

predominant initiation site.

There is a 40% sequence homology

between the

eDNA

of

PDGF

and a

putative

cDNA and the

CTGF

for both the

49% homology with the

alternative

splicing

region

CEF-10

is

A

and B chains
cDNA.

If a

deleted,

nucleotide homology to the CEF-IO mRNA increases to 59%.
3

1

region

contains

three

copies

of

the

the
The

pentanucleotide

sequence ATTTA shown to be involved in mRNA destabilization
and frequently found in growth factor and oncogene eDNA 3 1
regions (Shaw and Kamen,1986).
The CTGF open reading

frame encodes a 349 amino acid

peptide which contains 39 cysteine residues,

indicating a

protein of complex structure wi th roul tiple intramolecular
disulfide bonds.

This may explain the shift in mobility

observed on polyacrylamide gels following reduction of the
molecule with di thiothrei tol.

The amino terminal

of the

peptide contains a hydrophobic signal sequence indicative of
a secreted protein and there are two N-lirtked glycosylation
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sites at asparagine residues 28 and 225 in the amino acid
sequence.

The

(proline)

and

region
208

of the

(alanine)

protein

is

the

between

sequence

residue
of

the

32

CTGF

peptide included in the fusion protein produced by clone DB60
in lambda gt11 and bound the anti-PDGF antibody in the library

screening process.

There is a 45% overall sequence homology

between the CTFG peptide and the protein encoded by the CEF-

10 mRNA transcript and the homology
putative

rises to

52% when a

region is deleted.

alternative splicing

39

All

cysteine residues in each peptide can be aligned with few gaps
in the sequences.

The region between amino acid residues 171

(aspartic acid) and 199 (cysteine) in the CTGF peptide has no
significant homology to the corresponding region in the CEF10

sequence

acids

(amino

shorter.

This

incurred

during

168-224)

evolution

is

28

be

due

to

chicken

and

human

CQuld

discrepency

of

and

amino

acids

differences
genes.

Significantly,this region is bordered by areas of very high
homology

(85%

identity)

between the two molecules and may

indicate alternative splicing mechanisms in the expression of
this gene.
acid

at

The codens for lysine at residue 170 and aspartic
residue

consistent with a

171

3I

together
exon/5 I

form

exon

the

AAG/G

junction.

sequence

Alternative

splicing is found in other growth factor transcripts.

The

PDGF

the

A chain

gene

exibits

alternative

splicing

with

transcript produced in glioma cell line containing a highly
basic exon of 18 amino acids that is absent in the A chain
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transcript

produced

al.,19B?).

The Vascular Endothelial Growth Factor (VEGF) is

a

46

kd

vascular

dimeric

endothelial

by

protein

endothelial

cells

with
and

cells

mitogenic
having

a

(Collins

specificity
20%

amino

et

for
acid

homology to the PDGF A and B chain genes (Leung et al.,1989;
Keck et al.,1989).

Internal alternative splicing near the

carboxy terminal adds 44 amino acids to the monomer (Tischer
et a1.,1989).

The biological significance of both of these

splicing events has not yet been determined.
Our data demonstrate

that vascular endothelial

cells

grown in monolayer in vitro with 20% fetal calf serum present
in the media constitutively secrete the CTGF peptides.

The

retinal pigment epithelial cells also constitutively secrete
this molecule, but TGF-p stimulation increases production of
the protein.

Human dermal fibroblasts only secrete the CTGF

peptide and express the mRNA after stimulation with TGF-p (10
ng/ml

in

serum-free

media).

There

is

no

PDGF-related

biological activity in the conditioned media of cells which
have not been stimulated with
also

shown

to

express

the

TGF-~.

The fibroblasts were

PDGF A chain

mRNA

upon

TGF-13

incubation, but immunoblots of the affinity purified proteins
from conditioned media using the PDGF A or B chain specific
anti-sera indicated very little production of A chain peptide
in relation to the CTGF molecules.
purified proteins

The fact that the affinity

from the conditioned media

from primary

cultures of these three cell types have similar biological
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activity, produce the same pattern of peptides on immunoblots
with

an

anti-POOF antibody and express

a

single

2.4

kb

transcript on Northern blots with the clone DB60R32 as a
probe, but only under conditions in which the proteins are
secreted, argues strongly that the proteins are products of
the CTGF gene.
By using subtractive and differential screening, simmons
et al.

(1989)

cloned the CEF-10 mRNA which was one of 12

identified eDNA sequences transcribed from mRNA's that were
induced soon after the production of the src phosphoprotein
pp60 v-src

in

chicken

embryo

fibroblasts

transfected with

a

temperature sensitive vector containing a src eDNA insert.
The CEF-10 mRNA was induced in non-transfected CEF cells when
the serum concentration in the culture media was increased
from 0.5% to 10%.

The src protein and serum induce the

expression of the "immediate early genes" necessary for the
GO-G 1

transition in the cell cycle (Rollins and Stiles,1989 for

review).

One

major

group

of

these

genes

consist

of

intranuclear DNA-binding proteins including fos, myc and jun
which are essential for cell cycle regulation.
major

group

of

genes

induced

by

serum

and

The other
src

secretory proteins with cytokine characteristics.

produce
One of

these is the JE gene (Cochran et al.,1983) which has a cDNA
sequence with significant homology to the cytokines Macrophage
Colony

Stimulating

Factor

(M-CSF) ,alpha

interluken-2 (Rollins et al.,1988).

interferon

and

Another is the murine KC
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gene (Cochran et al.,19S3) which is homologous to the gro gene
in humans (Oquendo et al.,1989; Anisowicz et al. / 19S7).

The

gro protein product is related to CEF-4, another src and serum
inducible mRNA cloned from CEF cells
Sugano et al. / 19B7).

(Bedard et al., 1987;

It is significant that other secreted

proteins induced by src and serum in this system have cytokine
and growth factor activities which is consistent with our
findings for the CTGF protein.
The

PDGF

molecule

the

is

competence growth factor in serum.
indicate

that

the

CTGF

predominant

identified

The data presented here

molecule

has

biological

activity

similar to PDGF and binds the PDGF cell surface receptor.
CTGF may be another competence factor which could function in

many biological processes involving the growth of connective
The fact that we find CTGF secreted by vascular

tissue.

endothelial cells indicates that the peptide could be present
in serum.

The conditions under which the protein would be

secreted in vivo are not yet known.

The in vitro conditions

of endothelial cells growing in monolayer may resemble those
during angiogenesis.
could

facilitate

secretion of CTGF during angiogenesis

the

growth

of

smooth

muscle

cells

and

fibroblasts, thereby forming a matrix and substrate for the
continued

growth

neovascularization.
cells and

TGF-~

of

the

endothel ial

cells

and

The secretion of CTGF by both endothelial

stimulated fibroblasts could be important in

wound healing and tissue repair.

Immediately after formation
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of a wound, platelets present at the site would secrete PDGF
and TGF-p.

The PDGF would be mitogenic for the fibroblasts

and smooth muscle cells present and set up a

chemotactic

gradient to bring more of these cells to the wound site.

is

quickly cleared

from wound

fluid

so the

PDGF

CTGF peptide

secreted by endothelial cells and TGF-/3 stimulated fibroblasts
would

continue to

serve

as

a

competence mitogen

proliferation of connective tissue cells.
CQuid also playa role in atherosclerosis.

for

the

The CTGF protein
PDGF mRNA has been

detected in arterial tissues (Barrett and Benditt,1987) and
the message appears to be elevated in atherosclerotic lesions
(Barrett and Benditt,1988).

The secretion of CTGF peptides

by endothelial cells would stimulate the chemotaxis and growth
of smooth muscle and fibroblasts at the plaque site, thereby
aggrivating vessel

blockage.

Whether

CTGF production

is

required for transformation by the src oncogene remains to be
determined but it is interesting that CTGF could function as
an autocrine growth factor for src transformed fibroblasts.
Experiments to determine the transforming potential of the
CTGF cDNA are underway.
currently in the lab, work is underway to determine more
information

concerning

significance of CTGF.

the

biochemistry

and

biological

In order to examine genomic structure,

fragments of the cDNA are being used as a probe to screen
human genomic libraries.

These genomic clones will enable us

to examine the 5' end of the gene for transcription regulatory
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sites and to examine the intron/exon structure of the gene.
We

are

particularly

interested

in

alternative

splicing

mechanisms which may be involved in the expression of this
gene,

the

tissues and cell

transcripts,

types which express alternate

and the differences in biological function of

these proteins.

The CTGF eDNA will also be used to probe RNA

from various cell types and tissues to determine expression
of the transcripts.

Internal primers for peR reactions will

be made to examine and clone possible splicing alternatives
from eDNA of the different cell types used.

The eDNA for CTGF

will also be used to probe wound chamber RNA for expression
of this gene during various stages of wound healing.

It will

also be interesting to probe embryonic tissue and samples from
pathological conditions such as atherosclerotic tissue and
solid tumors for the expression of CTGF to determine the
involvement of this mitogen in development and disease.
oncogenic

potential

of

CTGF

will

be

investigated

The
by

transformation of mesenchymal cells with the CTGF eDNA in
expression vectors.

Concurrently with these experiments with

the cDNA and gene of CTGF,

we will also be examining the

expression and secretion of the CTGF protein with antibodies
specific to synthetic peptides representing various segments
of the molecule.

Furthermore, in order to conduct biological

studies with pure CTGF, we will produce recombinant CTGF by
recombinant methods in a bacterial or eucaryotic expression

system.

The goal of these investigations is a

thorough
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understanding of the CTGF protein, the gene which encodes it
and

the

biological

functions

pathological tissue growth.

of

CTGF

in

normal

and
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EXPERIMENTAL PROCEBDURES
CELLS

Human

obtained
Jaffe

umbilical

endothelial

(HOVE)

cells

were

from human umbilical cords by a modification of

(1973).

delivery

vein

rooms

Cords

and

were

placed

obtained
into

sterile Tris buffered saline (50

a

mM

from

sterile

local
cup

hospital

containing

Tris;BioRadil00 mM sodium

chloride,FisheripH 7.4) and could be stored for up to 12 hours
after birth at 4 C before use.

Only normal, heal thy cords were

obtained and only sections without clamp marks were used to
collect cells to avoid smooth muscle cell contamination of

cuI tures.

Cords were removed from the container under a

vertical flow hood and placed in a sterile tray with enough
Modified Tyrodes Solution (MTS)
potassium

(140 roM sodium chloride;3 roM

chloride, Fisher;O.3

rnM

sodium

phosphate

monobasic,Fisher;5 mM dextrose,Fisher) to wet cord and wash
off coagulated blood.

A piece of sterile Tygone tubing was

placed into one end of the vein, clamped with a plastic cable
tie and the cable tie secured with suture to the tubing.

A

60 ml syringe was connected to the tubing by way of a valve
and approximately 30 mls of MTS was forced through the vein
to remove blood clots and cells.

A short piece of Tygone

tubing is then inserted into the other end of the vein and
secured with cable tie and suture.

Approximately 15 mls of

a sterile 0.2% solution of Collagenase type IV (Worthington

Biochemicals) in MTS was put into the vein by the syringe and
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the other end of the vein closed off using a hemostat on the
tubing.

The cord was placed into a 37 C water bath for 20
After incubation in the water bath, the cord was

minutes.

removed and briefly massaged with fingers to loosen cells.
Approximately 30 mls of MTS was then forced through the vein
with the syringe and the cells collected in a sterile 50 ml
conical tube.

The cells are pelleted by centrifugation at

400 g for 10 minutes and resuspended in 5 mls of culture media
(

Media

199,Sigma;20%

fetal

calf

serum, Hyclone i 50

Endothelial Cell Growth Supplement, sigma

Fibroblast

Growth

Factor); 90

ugjml

Gentamicin,Quality Biological).

(a prep.

ug/ml

of basic

heparin, sigma; 10

ugjml

The cells were then placed

in a 25 ml tissue culture flask (Costar) which was previously
coated with sterile 2% gelatin solution (Sigma).

The cells

were grown at 37 C in an atmosphere of 95% air,5% CO2 •

After

reaching

(0.1%

confluence, the

cells

were

trypsinized

trypsin, Sigma; 0 .1% EDTA, sigma in phosphate buffered saline
(PBS)

(120 roM sodium chloride,2.7 roM potassium chloride in 10

mM phosphate buffer,pH 7.4,premixed from Sigma) and passaged
into a 75 ml culture flask.

One or two more passages of the

cells

split.

were

made

at

a

1:3

Conditioned media

collected from the second and third passage cells.
changed every other day.

was

Media was

Cells were identified as endothelial

cells by their non-overlapping cobblestone morphology and by
positive immunohistochemical staining for Factor-VIII related
antigen

(anti-Factor VIII antibody from Dako Corp.).
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Normal

Rat

Kidney

(NRK)

fibroblasts

were

obtained

American Type Culture and NIH 3T3 cells were a
S.Aaronson

(NCI,Bethesda,MD),and

maintained

in

(DMEM),(Sigma) ,10%

both

Dulbeco's

Modified

fetal

serum,20

calf

cell

from

gift from

lines

Eagles
ug/ml

were
Medium

Gentamicin.

Fetal bovine aortic smooth muscle cells were obtained from
tissue

explants

(Grotendorst

et

al.,1981),maintained

in

DMEM,10% fetal calf serum,20 ug/ml Gentamicin and used in
assays at second or third passage. Foreskin fibroblasts were
grown from explants of newborn human foreskins and cultured
in DMEM,lO% fetal calf serum,lO ug/ml Gentamicin.

Cells were

used no later then the tenth passage.

GROWTH FACTORS AND ANTIBODIES

Human PDGF was purified to homogeneity from platelets as
described previously (Grotendorst, 1984).

Recombinant AA, BB,

and AB chain dimeric

were

creative Biomolecules,

PDGF molecules
(Hopkinton, MA).

obtained

from

Porcine TGF-p was

obtained from Rand D Systems, Inc. Minn. MN.

FGF was obtained

from Sigma.
Purified PDGF or synthetic peptides 30 amino acids in
length containing the amino and carboxy sequences of the
mature

PDGF

antibodies
purified

A

and

B

in goats.

PDGF

or

50

chain molecules

were

used

to

raise

Goats were immunized with 20 J.l.g of
p,g

of

synthetic

peptide

in

complete adjuvant by multiple intradermal injections.

Freunds
Immune
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sera were collected seven days after the fourth rechallange
(in Freunds incomplete adjuvant) and subsequent rechallanges.
The anti-PDGF antibody did not show any cross-reactivity to
TGF-~,EGF,or

FGF in immunoblot analysis.

The anti-peptide

antibodies were sequence specific and did not cross-react with
other synthetic peptide sequences or with recombinant PDGF
peptides

which

sequence.

did

not

contain

the

specific

antigenic

This was determined by immunoblot and dot blot

analysis.

ANTIBODY AFFINITY COLUMN
Goat anti-human PDGF IgG (150 mg) was covalently bound

to 25 mls of Affi-Gel 10 support (BioRad) according to the
manufacturers instructions with a final concentration of 6 mg

IgG/ml gel.

The column was incubated with agitation at 4°C

for 18 hours with 1 liter of HUVE cell media which had been
conditioned for 48 hours.

The gel was then poured into a

column (5 x 1.5 em), washed with four volumes of 0.1 N acetic
acid made pH 7 . . 5 with ammonium acetate, and the antibody-bound
PDGF immunoreactive proteins eluted with 1 N acetic acid.
Peak fractions

were

determined by biological

assays

and

immuunoblotting and the fractions pooled.

CELL LABELING AND AUTORADIOGRAPHY
Confluent cultures of HUVE cells in 75 cm2 flasks were
labeled by incubating the cells for 22 hours in cysteine-free
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DMEN containing 250 ~Ci/ml of ~S-cysteine (Amersham), 20% FCS
(previously

dialyzed

in

cysteine-free

DMEM) ,

Endothelial Cell Growth Supplement,Siqma,90

~g/ml

~g/ml

40

heparin and

The ~S-labeled PDGF-immunoreactive proteins were

gentamicin.

affinity purified from the media with the Affi-Gel 10/anticolumn

PDGF

and

aliquots

polyacrylamide gels.
prepared

with

of

the

proteins

run

on

12%

As a control, an identical column was

Affi-Gel

10

and

non-immune

goat

IgG.

The

proteins were electroblotted to nitrocellulose and processed
as for Western blotting using the anti-human PDGF IgG as a
primary antibody.
autoradiographed

The nitrocellulose membranes were then
on

Kodak

film,

and

the

amount

of

36

kD

peptide determined using a Hoeffer densitometer and Gelscan
software (Hoeffer Scientific).

BIOLOGICAL ASSAYS
Chemotactic activity was determined in the Boyden chamber
chemotaxis assay with bovine aortic smooth muscle (BASM) cells
or

NIH

3T3

cells

al.,1981,1987).
were made up

(BSA).

added

as

previously described

(Grotendorst et

Briefly,the chemotactic samples to be tested

in serum-free DMEM, 0.2% bovine serum albumin

Anti-PDGF IgG,if added to neutralize activity,was
at

30

~g/ml

Approximately 250

~l

and

incubated

at

4

C

overnight.

of test sample was put into the bottom

chamber of a Modified Boyden Chamber and a Nuclepore filter
(8 ~m pore size)

which was previously coated with collagen
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type I,was placed over the sample and the top chamber which
holds the target cells was secured.

The target cells were

prepared by trypsinization for no more than two minutes to

prevent

PDGF

receptor

down

regulation.

cells

The

were

suspended in DMEM,2 mg/ml BSA,pelleted by centrifugation,and
resuspended in DMEM,O.2 mg/ml BSA at a concentration of 3 X
10 5 cells per milliliter.

Human fibronectin was added at a

concentration of 5 mg/ml.

Aliquots of approximately 810

of

was

cells

added

to

the

chamber

top

and

the

~l

chambers

incubated for four hours in a humidified incubator at 37 C in

an

atmosphere

of

90%

air ,10%

CO 2 •

After

incubation, the

filters were removed and the cell nuclei stained with Diff-

Quik

(American Scientific Products)

fixative

and staining

solutions.

The top layer of cells which did not migrate into

the

of

pores

policeman.

the

filter

was

scraped

off

with

a

rubber

The cells which migrated into the pores of the

filter due to the action of the chemoattractant were either

counted or quantitated by placing the filters into the

wells

96 well plate,extracting the dye with dilute Hel,and

of a

reading the absorbance at 600 nanometers with an ELISA reader.
Mitogenic assays were performed using 96 well plates and
normal rat kidney (NRK) fibroblasts or NIH 3T3 cells as target
cells.

The cells are plated in DMEM, 10% FCS and the NRK cell

cultures

used

10-14

days

after

confluence

and

3T3

cells

quiesed for 2 days in serum-free DMEM, 0.2 mg/ml BSA before
use.

Sample proteins and dilutions of known standards are
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added to the wells and the plates incubated at 37°C in 10%
CO2 , 90% air for 18 hours, after which

~-thymidine

(Amersham)

at a final concentration of 5

~Ci/ml

for an additional 2 hours.

The media was removed and the

was added and incubated

cells washed with cold PBS. The cells were then washed five
times

with

precipitate

a

cold

the

solution

of

macromolecules.

trichloroacetic
The

acid

macromolecules

to

were

removed from the wells in a solution of 0.1 N NaOH,O.l% sodium
dodecylsulfate
from the
by

3H

(5DS)

(BioRad)

and DNA synthesis determined

-thymidine incorporation into the newly formed DNA

scintillation counting.

RECEPTOR COMPETITION ASSAYS

Assays were performed using confluent cultures of NIH 3T3
cells in 24 well plates (Costar) grown in DMEM,lO% fetal calf
serum,lO

~g/ml

Gentamicin.

The growth media was removed and

the cells washed twice with serum-free DMEM,O.2 mg/ml BSA and
the plates placed on ice for 30 minutes in serum-free DMEM,O.2
mg/ml BSA.

Test samples and controls were made up in serum-

free DMEM,O.2 mg/ml BSA containing 5-10 ng/ml of HUVE affinity

purified

proteins

and

a

serial

dilution

of

one

of

the

recombinant PDGF isoforms in a concentration range of 300
ng/ml to 16 ng/ml.

One milliliter aliquots of the samples

were placed into wells of the 24 well plates and incubated on
ice on a platform rocker for two hours.

After the incubation

period,the cells were washed three times for 10 minutes each
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on ice with PBS.

The proteins bound to the surface of the

cells were eluted with 500 ul

minutes.

The

acetic

of 1

acid

N acetic

elution

acid for

samples

10

were

lyophilized,resuspended in 5 mM HCL,run on 12% polyacrylamide
gels and immunoblotted to nitrocellulose using the anti-PDGF
antibody.

GEL ELBCTROPHORESIS AND IMMUNOBLOTTING

Electrophoresis

performed

was

(National Diagnostics,Manville,NJ)

on

polyacrylamide

12%

separating gels with 4%

stacking gels containing SOS (Laemmli,1970) unless otherwise
stated.

The gels were run on mini-gel apparatus

Small" Hoeffer Scientific).

("Mighty-

Immunoblotting was performed by

electroblotting the proteins to

a

nitrocellulose membrane

(Schleicher and Schuell,45 um pore size). Electroblotting was
done using the "Multiphor II" blotting apparatus (BRL)

in a

buffer of 0.025 M Tris,O.192 M glycine,20% methanol,pH 8.3.
The membrane was incubated in 50 roM Tris-HCl, pH 7.4, 100 mM
NaCl (TBS) with 5% non-fat dry milk (Carnation) at 25°C for
1 hour to block non-specific antibody binding.
solution was removed and the antibody (15
containing 0.5 % non-fat dry milk and 1
incubated overnight at 2S C.
Q

~g/ml)

~gjml

The blocking
added in TBS

sodium azide and

The membranes were then washed

5 times in TBS, 0.5% milk for 10 minutes each wash and then
incubated
purified

with
rabbit

alkaline

phosphatase

anti-goat

IgG

conjugated

(Organon

affinity

TeknikajCappel,
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Malvern,PA) at a 1:1000 dilution in TBS containing 0.5% milk
at 25°C for 1 hour.

The filters were then washed with TBS

five times, 10 minutes each time, and the blot developed using
an alkaline phosphatase substrate solution (0.1 M Tris-Hel,
pH 9, 0.25 mg/ml nitro blue tetrazolium,Sigma; 0.5 mg/ml 5-

bromo-4-chloro-3-indolyl phosphate,Sigma).

RNA ISOLATION AND NORTHERN BLOTTING

Total RNA was isolated from tissue culture cells by the
method of Chomczynski and Sacchi (1987).
were

lysed

guanidinium

in

the

culture

thiocyanate,Boehringer

citrate,pH

7.0,Sigma;O.5%

mercaptoethanol, BioRad.
of

in

flask

mixing.
minutes

solution

a

Mannhiem;25

4

C

M

sodium
2-

To the lysed cells solution,1/10 vol.

alcohol

and

4

M

were

phenol,1/5 vol.

added

sequentially

The solution was centrifuged at 10,000 9
at

of

mM

sarcosyl,sigmaiO.l

2 M sodium acetate,pH 4,equal vol.

chloroform/isoamyl

Cells in monolayer

the

RNA

in

the

aqueous

of

with

for 20

phase

was

precipitated with an equal volume of isopropanol at -20 C for
1 hour.

The RNA was pelleted by centrifugation and the pellet

resuspended in the above guanidinium thiocyanate solution and
again precipitated with isopropanol.
Lyophilized RNA was resuspended in gel loading buffer of
50% formamide,lX MOPS

sodium

acetate, 1

roM

(20 roM MOPS Boehringer Mannheim,5 roM

EDTA, pH

8 . 0) , 6 .7%

glycerol,bromophenol blue and heated at 95

formaldehyde, 6%

C for two minutes
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before

loading

(20

~g

per

lane

total

RNA)

onto

2.2

M

formaldehyde,1% agarose gels and run at 50 volts. Integrity
of

RNA

was

determined

by

ethidium

bromide

visualization of 18S and 28S rRNA bands.

staining

and

After the run, gel

was soaked in 10 X sse (lX,O.15 M NaCl,0.015 M sodium citrate)
for

40

min.

total

with

one

solution

change.

RNA

was

transfered to nitrocellulose by blotting overnight with 10 X

sse.

The nitrocellulose was air dried and baked at 80 C for

2 hours in a vacuum oven.

The membrane was prehybridized for

30 min. at 46 C in a solution of 50% deionized formamide,0.9
M NaCl,50 mM sodium phosphate pH 7.0,5 mM EDTA,2X Denhardts
solution,O.l% 8D8,75
sperm DNA,5

~g/ml

~g/ml

tRNA,100

~g/ml

poly-A RNA (all Sigma).

depurinated salmon
Hybridization is

overnight at 46 C in the same solution with the addition of
5 X 105 CPM per ml of

32

P -l a beled probe.

Normally for Northern

blots the entire plasmid was labeled and used as a probe.
Labeling was done with

a

random prime

labeling kit

Boheringer Mannheim according to instructions provided.

from
After

hybridization,membranes were washed twice in 2X SSC,O.l% SDS
for 15 minutes each at room temperature, once for 15 minutes
in O.IX SSC,O.l% 5DS,room temp. and a final 15 minute wash in
O.lX SSC,O.I% SOS at 46 C.

-70 C on Kodak X-omat film.

Blots were autoradiographed at
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DNA CLONING, SEQUENCING AND LIBRARY SCREENING
Standard

molecular

biology

techniques

were

used

to

subclone and purify the various DNA clones (Sambrook et al.,
1989).

Clone DB60 was picked from a lambda-gtll HOVE cell

cDNA library by induction of the fusion proteins and screening
Approximately 2 x 10 5 phage were

with anti-PDGF antibody.

incubated

with

JLI

600

of

an

overnight

of

culture

YI090

bacteria at 37 C for 20 minutes. The phage infected bacteria
were plated in 0.6% top agarose

1.5% bottom agarose
Fisher)

(Boehringer Mannheim)

(LB medium)

and placed in a

visible (approx. 6 hrs).

plates

onto

(150 rom diameter,

42 C incubator until plaques were
~m

Nitrocellulose circles (45

pore

size,Schleicher and Schuell) previously soaked in 10 roM IPTG
(5 1 -3',Inc.) and dried were placed on top of the plaques on
the agarose plates and the plates incubated at 37 C for 2

This

hours.

process

induced

production

of

the

beta-

galactosidase/human cDNA fusion protein by the phage.

The

nitrocellulose membranes were then removed from the plates, the
plates placed at 4 e,and the membranes placed in a blocking
solution of Tris-buffered saline
NaCl,pH

7.4)

agitation

at

and
room

5%

nonfat

dry

temperature

(TBS)
milk

for

1

(50 roM Tris,lOO mM
and

incubated

hour.

The

with

blocking

solution was removed and anti-PDGF IgG (previously incubated
overnight

with

nonspecific

a

Y1090

antibody

concentration of 3

cell

binding

~g/ml

lysate
to

in

bacterial

TBS

to

prevent

proteins)

at

a

in TBS with 0.5% nonfat dry milk was
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added in sufficient volume to cover the membranes was added
and the containers placed on a rocker at 4 C for at least 12

hours.

The membranes were washed with TBS,O.5% milk five

times for 15 min. each time.
anti

goat

IgG,alkaline

concentration

of

1

J,Lg/ml

The secondary antibody,rabbit

phosphatase

conjugated

in TBS, o. 5% milk was

incubated at 4 C for 1 hour with agitation.

at

a

added and

The membranes

were again washed with TBS,O.5% milk five times for 15 min.
each.

Alkaline phosphatase substrate solution (0.1 M Tris,pH

9.0,0.25 mg/ml nitro blue tetrazoleum,O.5 mg/ml 5-bromo-4chloro-3-indolyl phosphate) was added and incubated at room
temp.

The solution was changed several times and a

solution usually left on overnight.

fresh

The membranes were dried

and positive clones (as indicated by circles of precipitate
from the alkaline phosphatase substrate solution)

picked by

matching the membranes with the plaques on the agarose plates.
Plaques picked were rescreened and positive clones replated
at low titer and isolated.

The EcoR I insert from clone DB60 was cloned into the M13
phage vector and single stranded DNA obtained for clones with
the insert in opposite orientations.

These M13 clones were

then sequenced by the dideoxy method (Sanger, 1977) using the
Sequenase kit (U. S. Biochemical) and ~S-dATP.

Both strands

of DNA for this clone were completely sequenced using primer
extension and both GTP and ITP chemistry.
reactions

were

done

according

to

the

The sequencing

manufacturors

79

instructions.

Aliquots of the sequencing reactions were run

on both 6% acrylamide (16 hours) and 8% acrylamide (6 hours)
gels,vacuum dried and autoradiographed for at least 18 hours.
The eDNA fragment from clone DB60 was ~P-CTP labeled and
used to rescreen the HUVE cell eDNA lambda gt11 library.

Approximately 100,000 recombinants were plated and rescreened
by standard methods

clone

designated

phagemid.

(Sambrook et al., 1989) •

DB60R32

was

subcloned

into

Bluescript

Subclones were made of Pst I,Kpn I,and Eco RI/Kpn

I restriction fragments also in Bluescript.
were

The 2100 bp

sequenced by double

stranded

These subclones

plasmid

DNA

techniques using Sequenase as described above.
Eco RljKpn I

sequencing
The 1458 bp

clone containing the open reading frame was

subcloned into M13 mp18 and M13 mp19 and both strands of DNA
were completely sequenced using single stranded DNA sequencing

techniques

with

primer

extension

and

both

GTP

and

ITP

chemistry.

IN VITRO TRANSCRIPTION AND TRANSLATION ASSAYS
In vitro transcription reactions were done using the 2100

bp

cDNA clone

DB60R32

in the

Bluescript

KS

vector.

The

plasmid was cut with Xho I which cuts the plasmid once in the
multiple cloning site of the vector 3' to the eDNA insert.
The T7 promoter site located 5' to the eDNA insert was used
for transcription.

The in vitro transcription,s were done with

a kit supplied with the Bluescript vector by stratagene and
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the manufacturors instructions were followed.
were done in a final volume of 25
Tris, pH 8. 0 . 8 mM MgC1 2 , 2

~1

The reactions

in a buffer of 40

mM

spermidine and 50 mM NaCl.

roM

In
~M

addition,the reactions contained 500 uM rATP,rUTP,rCTPi5
rGTPi500

~M

7meGpppG cap;30

~M

DTT;l

~g

Proteinase K treated

DB60R32,in Bluescript;l U RNase inhibitor and 10 U of T7

polymerase.

The reactions were incubated for 1 hour at 37 C.

The reaction mix was treated with RNase-free DNase for 15 min.
at 37 C, phenol:chloroform extracted and the RNA precipitated
with ethanol.
In vitro translation reactions were done using nuclease
treated

rabbit

reticulocyte

lysate

and

~S-cysteine

cysteine-free amino acid mix for labeling of the peptide.

in

a

The

reactions were done with a kit supplied from Promega and the

manufacturors instructions were followed.

The reactions were

done in a 'final volume of 50 ILl and included 35 J.l.l of the
supplied rabbit reticulocyte lysate,20
(minus cysteine)

14 U

JLM

amino

acid mix

RNase inhibitor, 35s - cysteine 1 mCijml (1200

Ci/mMole, DuPont) , and serial dilutions of mRNA from the in
vitro transcription reactions in concentrations ranging from
100 to 1000 nanograms per reaction tube.

The mRNA samples

were heat treated at 67 C for 10 minutes and cooled on ice
immediately before use.

C for 60 minutes.
on

12%

Aliquots of the reactions were run reduced

polyacrylamide

autoradiograhped.

The reactions were incubated at 30

electrophoresis

gels,

dried

and
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